Search
Menu
Home
HTB
2012
April
01
1 April 2012
Contents
Editorial
Volume 13 Number 3/4 March/April 2012
Special reports
Supplement: i-Base Introduction to Combination Therapy
Conference reports
19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012
Cure research takes centre stage: proof of concept for activating the latent reservoir
Quad fixed-dose integrase combination: phase 3 studies at week 48
Dolutegravir studies continue to show promise
Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation
Paediatric formulations of ARVs: including an exciting new class
Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART
High prevalence of d4T-associated lipodystrophy including lipoatrophy in children
Lopinavir/ritonavir monotherapy in children
Stopping treatment after early ART in infants
PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection
Risk of HIV reinfection may be similar to risk of initial HIV infection
Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus
No association between atazanavir and MI or stroke in D:A:D study
Hepatitis C coinfection studies
Herpes Zoster vaccine safe and effective in HIV positive people
High dose flu vaccine improves antibody responses in HIV positive people
Antiretrovirals
Dolutegravir Expanded Access Programme
FDA approves etravirine for treatment-experienced children 6 to 18 years of age and new scored 25 mg tablet for paediatric dosing
Treatment access
Why global health activists are fired up about Novartis
Obama’s global, domestic & HIV research budget backslides on existing commitments
PK and drug interactions
FDA warning of drug interactions between boceprevir and some HIV protease inhibitors
Guidelines
US HHS adult treatment guidelines updated (March 2012)
Side effects
FDA reject capsaicin patch for HIV-related neuropathy
Other news
Free comic book for HIV positive children about CD4, viral load and ARV treatment
On the web
Free full text online articles
PDFs
Volume 13 Number 3/4 March/April 2012 PDF
HTB RSS
Early access
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate